错配修复缺陷子宫内膜癌临床病理形态特征及临床意义被引量：7

Clinicopathologic features and clinical significance of endometrial carcinoma with mismatch repair deficiency

下载PDF

导出

摘要目的探讨碱基错配修复(MMR)缺陷子宫内膜癌的临床病理特征与临床意义。方法收集天津市中心妇产科医院常规开腹手术者中≤50岁内膜癌患者共108例,进行4种碱基错配修复(MMR)蛋白(MLH1、MSH2、MSH6及PMS2)的免疫组化检测,MMR蛋白表达完全缺失提示MMR基因缺陷,依据免疫组化结果进行分组。结果108例内膜癌中,33.3%(36例)至少1种MMR表达缺失。重点对36例MMR蛋白表达缺失患者行临床病理特征分析并与对照组比较。31%伴有深肌层侵犯,25%可见肿瘤细胞周围有密集的淋巴细胞浸润。35%的内膜癌患者合并黏液分化及透明细胞分化等多种分化方式,14%伴有异质性分化。20%患者同时合并卵巢癌。背景内膜多为增生期内膜。倾向深肌层侵犯、多样性分化与异质性分化、肿瘤周围淋巴细胞浸润、同时合并卵巢癌及背景内膜的特征与对照组相比差异有统计学意义。结论 MMR缺陷子宫内膜癌具有区别于传统Ⅰ型及Ⅱ型内膜癌的特征。 Objective To investigate the clinicopathologic features and clinical significance in mismatch repair （MMR） of deficient endometrial carcinoma. Methods A total of 108 endometrial carcinoma cases younger than 50 years of age who were underwent routine laparotomy in our hospital were included in this study. Immunohistochemistry staining was used for 4 MMR proteins （MLH1, MSH2, MSH6 and PMS2）. Patients were divided into two groups （MMR deficiency group and MMR normal group） based on the results of immunohistochemistry staining. Results Thirty-three percent of cases （36 patients） showed at least one deletion of MMR protein expression. The clinicopathological features of 36 cases with deletion of MMR protein expression were analyzed. The 31% showed deep myometrium invasion and 25% were with intense lymphocyte infiltration around tumor cells. Thirty-five percent of endometrial carcinomas associated with mucinous, clear cell or other differentiations, and 14% with heterogeneity. Background endometrium of majority of the cases displayed proliferative endometrium. There were 20% cases complicated with ovarian carcinoma. Features included deep myometrium invasion, lymphocyte infiltration around tumor cells, multiple differentiations and complicated with ovarian carcinoma. There were significant differences in background endometrium between endometrial carcinoma combined with ovarian cancer group and control group. Conclusion MMR deficient endometrial carcinoma has characteristic features, which are different from both type I and type II endometrial carcinoma.

作者彭芳华庞淑洁刘易欣

机构地区天津医科大学天津市中心妇产科医院

出处《天津医药》 CAS 2017年第12期1304-1307,共4页 Tianjin Medical Journal

关键词子宫内膜肿瘤基因结直肠肿瘤遗传性非息肉性免疫组织化学 MMR基因 LYNCH综合征 endometrial neoplasms genes colorectal neoplasms, hereditary nonpolypopsis immunohistochemistry MMR gene Lynch syndrome

分类号 R711.74 [医药卫生—妇产科学]

引文网络
相关文献

参考文献1

1毕蕊,涂小予,肖遥星,单波儿,王华英,蔡旭,周晓燕,杨文涛.子宫内膜癌错配修复蛋白表达的临床病理分析[J].中华病理学杂志,2016,45(5):302-307. 被引量：15

二级参考文献27

1Watson P, Riley B. The tumor spectrum in the Lynch syndrome [J]. Fam Cancer, 2005, 4 (3) : 245-248. DOI: 10. 1007/ s10689-004-7994-z.
2Lu KH, Dinh M, Kohlmann W, et al. Gynecologic cancer as a " sentinel cancer " for women with hereditary nonpolyposis colorectal cancer syndrome [ J ]. Obstet Gynecol, 2005, 105 ( 3 ) : 569-574. DOI : 10. 1097/01. AOG. 0000154885, 44002. ae.
3Schmeler KM, Lu KH. Gynecologic cancers associated with Lynch syndrome/HNPCC[J]. Clin Transl Oncol, 2008, 10(6) :313- 317.
4Garg K, Leitao MM, Kauff ND, et al. Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities[ J]. Am J Surg Pathol, 2009, 33 (6) :925-933.
5Shia J, Black D, Hummer A J, et al. Routinely assessed morphological features correlate with microsatellite instability status in endometrial cancer[ J]. Hum Pathol, 2008, 39 ( 1 ) : 116-125. DOI : 10. 1016/i. humpath. 2007.05. 022.
6Moreira L, Balaguer F, Lindor N, et al. Identification of Lynch syndrome among patients with colorectal cancer [ J ]. JAMA, 2012, 308(15) :1555-1565. DOI:10. 1001/jama. 2012. 13088.
7Lu KH, Schorge JO, Rodabaugh K J, et al. Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer [ J ]. J Clin Oncol, 2007, 25 ( 33 ) :5158- 5164. DOI:10. 1200/JCO. 2007.10. $597.
8Berends MJ, Wu Y, Sijmons RH, et al. Toward new strategies to select young endometrial cancer patients for mismatch repair gene mutation analysis[J]. J Clin Oncol, 2003, 21 (23) :43644370. DOI : 10. 1200/JCO. 2003.04. 094.
9Buchanan DD, Tan YY, Walsh MD, et al. Tumor mismatch repair immunohistochemistry and DNA MLH1 methylatiou testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing[J]. J Clin Oncol, 2014, 32(2) :90- 91. DOI : 10. 1200/JCO. 2013.51. 2129.
10Moline J, Eng C. Equality in lynch syndrome screening: why should we hold patients with endometrial cancer to a different standard[J]. J Clin Oncol, 2014, 32 (21) : 2277. DOI: 10. 1200/JCO. 2014.55. 3602.